Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes
Open Access
- 1 April 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (7) , 3180-3187
- https://doi.org/10.1158/0008-5472.can-08-3691
Abstract
A major parameter limiting immune responses to vaccination is the number of activated antigen-presenting cells (APC) that capture antigen and migrate to draining lymph nodes (LN). Currently, a quantitative noninvasive technique for monitoring in vivo antigen capture and delivery is lacking. The use of cellular magnetic resonance (MR) imaging (MRI) is a promising approach for this purpose; however, cellular imaging currently requires ex vivo prelabeling of cells with contrast agents followed by reintroduction of cells into the subject being monitored. Here, we describe an in vivo labeling method, which relies upon cell-to-cell transfer of superparamagnetic iron oxide (SPIO) from tumor cells to endogenous APCs, in situ, to quantify APC delivery to LNs in a tumor vaccine model. Mice were immunized with a tumor cell–based vaccine that was irradiated and labeled with SPIO. APCs that had captured SPIO were imaged over time as they accumulated in LNs. We show here that MRI is capable of monitoring, in vivo, the trafficking of magnetically labeled APCs inducing a tumor-specific immune response, and that these cells can be magnetically recovered ex vivo. Excellent correlation was observed between in vivo and ex vivo quantification of APCs, with resolution sufficient to detect increased APC trafficking elicited by an adjuvant. This study shows the potential of magnetovaccination and MRI cell tracking to systematically evaluate a key parameter relevant to the optimization of vaccine therapies through noninvasive MRI-based quantification of APC numbers. [Cancer Res 2009;69(7):3180–7]Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Tumor-specific Th17-polarized cells eradicate large established melanomaBlood, 2008
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- Dendritic cell immunotherapy: mapping the wayNature Medicine, 2004
- Preparation of Magnetically Labeled Cells for Cell Tracking by Magnetic Resonance ImagingPublished by Elsevier ,2004
- Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo MaturationThe Journal of Immunology, 2003
- Class I–restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8+ T CellsThe Journal of Experimental Medicine, 1997
- In Vivo Cross-Priming of MHC Class I–Restricted Antigens Requires the TAP TransporterImmunity, 1996
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.The Journal of Experimental Medicine, 1994
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993